Good news and bad news for Achaogen's antibiotic candidate

4 May 2018

Mixed messages from the US Food and Drug and Administration’s advisory panel unsettled Achaogen (Nasdaq: AKAO) shareholders this week, with the vote falling in favor of approval of the antibiotic plazomicin for complex urinary tract infections (cUTI) but not for its use against bloodstream infections.

Plazomicin is an aminoglycoside that was developed to treat serious bacterial infections due to multidrug resistant gram-negative bacteria.

The panel voted unanimously in favor of approval for the candidate for cUTIs, but 11-4 against for bloodstream infections. While the FDA is not bound by the panel’s view, it usually follows its advice.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK